Atsena Presents Positive Interim Six-Month Results From Part B of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients With X-Linked Retinoschisis (Globe Newswire)
UF startup Atsena Therapeutics reported encouraging six-month clinical trial results showing improved vision and a favorable safety profile for its gene therapy targeting X-linked retinoschisis.
Kriya Announces Presentations at ASGCT 2026 Highlighting Advances Across Gene Therapy Platform (Globe Newswire)
UF startup Kriya Therapeutics will present multiple gene therapy advances at the 2026 ASGCT Annual Meeting, highlighting its efforts to make treatments for chronic diseases more accessible.
FDA Approves First Gene Therapy for Inherited Deafness, Shown To Restore Hearing for Children With Rare Condition (CNN)
Regeneron, which licenses technology developed by UF researcher Sanford Boye and team, is advancing gene therapy research that could restore hearing in people with inherited deafness.
UF Scientist Develops Safer Gene Therapy To Restore Vision (Gainesville Sun)
UF researcher Dr. Shannon Boye has developed a safer gene therapy now in clinical trials that is already helping patients with inherited eye diseases regain vision.
Solid Biosciences Doses First Patient in Phase 1b FALCON Trial for Friedreich’s Ataxia (Solid Biosciences)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that the first participant has been dosed in FALCON, the Company’s Phase 1b, first-in-human clinical trial evaluating SGT-212, its investigational gene therapy for the treatment of Friedreich’s ataxia (FA).
Atsena Completes Part B Dosing and Advances to Pivotal Part C of LIGHTHOUSE Trial (Atsena Therapeutics)
UF startup Atsena Therapeutics announced that dosing is complete in patients enrolled across all adult and pediatric cohorts in Part B of the Phase I/II/III Lighthouse Trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia (Globe Newswire)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that it received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) for SGT-212, the Company’s investigational gene therapy for Friedreich’s ataxia (FA).
Gene Therapy Specialist Kriya Raises $313M (Bio Space)
UF startup Kriya is advancing a host of gene therapies for a wide variety of chronic diseases, including geographic atrophy, trigeminal neuralgia and type 1 diabetes.
NIH Award Supports New Extracellular Vesicle Loading Platform To Develop Gene Therapy
UF researcher Mei He, Ph.D., has received a $1.3 million award from the National Institutes of Health to support a new extracellular vesicle platform used to develop gene therapy.
Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing To Further Advance Ocular Gene Therapy Programs
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on reversing or preventing blindness, announced the successful close of an oversubscribed $150 million Series C financing round.